Ethacizine(diethylaminopropionylethoxycarbonylaminophenothiazine hydrochloride) 50 pills 50 mg
English product name
Ethacizine
Release form
tabb, shell 50 mg: 50 pcs
Description Ethacizine:
Tablets, covered with a shell of yellow color, round, double-convex; the cross section shows a nearly white core and a shell.
1 tab.
etacizin (diethylamine propionyl ethoxycarbonyl aminophenothiazine hydrochloride) 50 mg
Auxiliary substances: potato starch - 9.57 mg, sucrose - 19.3 mg, methylcellulose - 0.33 mg, calcium stearate - 0.8 mg.
Shell Composition: sucrose - 37.695 mg, powidon K25 - 0.753 mg, dye quinoline yellow (E104) - 0.025 mg, dye sunscreen yellow (E110) - 0.003 mg, calcium carbonate - 6.308 mg, magnesium hydroxicarbonate - 3.678 mg, titanium dioxide (E171) - 0.665 mg, silicon dioxide - 0.827 mg, wax carnauba - 0.046 mg.
10 pcs - box-type contour (5) packages - cardboard packs.
ATC codes Ethacizine
C01BC09 Ethacizine
Clinical-pharmacological groups / Group affiliation
Antiarrhythmic drug. Class I C
Active substance
diethylamine propionyl ethoxicarbonyl aminophenothiazine hydrochloride
Pharmacotherapy group Ethacizine:
Antiarrhythmic agent
Storage Conditions Ethacizine
The drug should be stored in a place inaccessible to children, protected from light at a temperature not higher than 25 ° C.
Best before date
The shelf life is three years.
Pharmacological effect Ethacizine:
It has a long-lasting antiarrhythmic effect. Depresses the rate of growth of the front of the action potential (Vmax), does not change the resting potential.
Depending on the dose may reduce the duration of the action potential. It does not significantly alter the effective refractory periods of ventricles and atrial fibrillation. Depresses fast incoming sodium current and, to a lesser extent, slow incoming calcium current.
Etacizin® slows down excitation of the conductive myocardial system. On the ECG appears an elongation of the PR interval and the QRS complex; The ST interval reflecting the repolarization of ventricles does not change or tends to shorten.
Etacisin® increases the threshold of myocardial fibrillation. In contrast to many antiarrhythmic drugs, Etacizin® does not cause a reliable reduction in NPO or lengthening of the QT interval on the ECG.
The antiarrhythmic effect of ingestion usually develops one to two days, the duration of treatment depends on the form of arrhythmia, effectiveness and tolerability of the drug.
Testimony Ethacizine:
- anjeludochka and gastric extracistolia;
- paroxysms of atrial fibrillation and fluttering;
- Ventricular and Najleductal tachycardia (including WPW).
- Indications for use are limited by the presence of severe organic damage to the heart.
Method of use, course and dosage Ethacizine:
The drug should be taken inwards regardless of the ingestion of fifty mg two - three times a day.
In the case of insufficient clinical effect, the dose is increased (under mandatory ECG control) to 50 mg four times/day (200 mg) or one hundred mg three times per day (300 mg).
Once a persistent anti-arrhythmic effect is achieved, maintenance therapy is carried out in individually selected minimum effective doses.
Nosology (ICD codes)
I45.6
Premature Arousal Syndrome
I47.1
Angeludic tachycardia
I47.2
Ventricular tachycardia
I48
Atrial fibrillation and fluttering
I49.4
Other and unspecified premature depolarization (extracistols)